PT  - JOURNAL ARTICLE
AU  - Lucia Baratto
AU  - Hong Song
AU  - Heying Duan
AU  - Negin Hatami
AU  - Hilary Bagshaw
AU  - Mark Buyyounouski
AU  - Steven Hancock
AU  - Sumit Anil Shah
AU  - Sandy Srinivas
AU  - Patrick Swift
AU  - Farshad Moradi
AU  - Guido A Davidzon
AU  - Andrei Iagaru
TI  - PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer
AID  - 10.2967/jnumed.120.259630
DP  - 2021 Mar 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.120.259630
4099  - http://jnm.snmjournals.org/content/early/2021/03/05/jnumed.120.259630.short
4100  - http://jnm.snmjournals.org/content/early/2021/03/05/jnumed.120.259630.full
AB  - Rationale: Novel radiopharmaceuticals for positron emission tomography (PET) are evaluated for the diagnosis of biochemically recurrent prostate cancer (BCR PC). Here, we compare the gastrin releasing peptide receptors (GRPR) - targeting 68Ga-RM2 with the prostate specific membrane antigen (PSMA) – targeting 68Ga-PSMA11 and 18F-DCFPyL. Methods: Fifty patients had both 68Ga-RM2 PET/MRI and 68Ga-PSMA11 PET/CT (n = 23) or 18F-DCFPyL PET/CT (n = 27) at an interval ranging from 1 to 60 days (mean±SD: 15.8±17.7). Maximum standardized uptake values (SUVmax) were collected for all lesions. Results: RM2 PET was positive in 35 and negative in 15 of the 50 patients. PSMA PET was positive in 37 and negative in 13 of the 50 patients. Both scans detected 70 lesions in 32 patients. Forty-three lesions in 18 patients were identified only on one scan: 68Ga-RM2 detected 7 more lesions in 4 patients, while PSMA detected 36 more lesions in 13 patients. Conclusion: 68Ga-RM2 remains a valuable radiopharmaceutical even when compared with the more widely used 68Ga-PSMA11/18F-DCFPyL in the evaluation of BCR PC. Larger studies are needed to verify that identifying patients for whom these two classes of radiopharmaceuticals are complementary may ultimately allow for personalized medicine.